Yahoo Finance Urothelial Carcinoma Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight
As per DelveInsight urothelial carcinoma pipeline involves 70+ key companies developing 70+ urothelial carcinoma treatment therapies
Las Vegas, USA, June 06, 2022 (GLOBE NEWSWIRE) -- Urothelial Carcinoma Pipeline Insights | Clinical Trials Evaluation Report 2022 | DelveInsight
As per DelveInsight urothelial carcinoma pipeline involves 70+ key companies developing 70+ urothelial carcinoma treatment therapies
DelveInsight’s Urothelial Carcinoma Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the urothelial carcinoma pipeline domain.
Some of the essential takeaways from the Urothelial Carcinoma Pipeline report:
DelveInsight’s urothelial carcinoma pipeline analysis depicts a robust space with 70+ active players working to develop 70+ pipeline treatment therapies
Some of the key urothelial carcinoma pipeline companies working to develop potential drug candidates to improve the urothelial carcinoma treatment scenario include Shandong TheraWisdom Biopharma Co., Ltd., Ikena Oncology, Ocellaris Pharma, Inc., Bayer, 4D Pharma PLC, MedPacto, QED Therapeutics, Bristol-Myers Squibb, Kyowa Kirin Pharmaceutical Development, Vyriad,Inc, Basilea Pharmaceutica, Pfizer, Daiichi Sankyo, Janssen Research & Development, LLC, Eli Lilly and Company, InnoCare Pharma, Kinnate Biopharma, Clovis Oncology, Gritstone Oncology, Xennials Therapeutics, Genome and Company , Exelixis, Atreca, Zentalis Pharmaceuticals, Celldex Therapeutics Inc , Nurix Therapeutics, Inc., Lipac Oncology LLC, TesoRx Pharma, LLC, Adaptimmune Therapeutics, Helsinn Group, Bicycle Therapeutics, Scholar Rock, Inc., Janux Therapeutics, Checkpoint Therapeutics, Inc., BioAtla, Inc., Cybrexa Therapeutics, Eisai Inc., Incyte Corporation, Shattuck Labs, Inc., Tempest Therapeutics, RAPT Therapeutics, Inc., Nektar Therapeutics, TAIHO PHARMACEUTICAL, Jazz Pharmaceuticals, Tyra Biosciences, Rubius Therapeutics, MacroGenics, BioNTech SE, Sorrento, and several others
Essential urothelial carcinoma therapies such as OC-001, IK-175, MRx 518, Rogaratinib, Vactosertib, Infigratinib, TWP-101, Ipilimumab, KHK 2455, MV-NIS, Derazantinib, Sasanlimab, Trastuzumab deruxtecan, TAR-200, Ramucirumab, ICP-192, KIN-3248, Rucaparib, GRANITE 001, NTX-301, GEN-001, XL092, ATRC-101, ZN-c3, CDX-527, NX-1607, TSD-001, CK-301, BA3071, CBX-12, E7130, INCB099280, SL-279252, TPST-1495, FLX475, NKTR-255, TAS0313, Lurbinectedin, TYRA-300, RTX-224, Enoblituzumab, GEN1046, Sti-3031, etc
In May 2022, Exelixis, Inc. announced detailed results from multiple cohorts of Phase Ib COSMIC-021 trials of cabozantinib (CABOMETYX^®) as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The company announced that they would be presenting the data from urothelial carcinoma (UC) cohorts 3, 4, and 5 and from non-small cell lung cancer (NSCLC) cohorts 7 and 20 during oral abstract sessions at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, June 3–7
In May 2022, Kinnate Biopharma Inc. announced the presentation of the design and rationale of a Phase I trial-in-progress (KIN-4802, NCT05242822) evaluating the company’s pan-FGFR inhibitor product candidate, KIN-3248. The company announced that they would be presenting the details during a poster session on June 6, 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO). In April 2022, Ikena Oncology, Inc. announced that it would be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The presentations will include overviews of the clinical trials for Ikena’s novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175
In March 2022, Juniper Biologics Pte Ltd and Helsinn Group, announced the signing of an exclusive license agreement to develop and commercialize infigratinib (INN) in Australia, New Zealand, Southeast Asia, and certain markets in the Middle East and Africa for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangements
Infigratinib is an orally administered, selective, ATP‐competitive, kinase inhibitor of FGFR 1, 2, and 3. The therapy is currently under investigation as a potential first-line treatment for individuals with unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 fusion/rearrangement and in the adjuvant setting for individuals with invasive urothelial carcinoma (bladder cancer) with susceptible FGFR3 genetic alterations
In April 2022, Bicycle Therapeutics plc announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4. The results were presented in an oral presentation on Sunday, April 10, at the 2022 American Association for Cancer Research Annual Meeting in New Orleans, LA
Request a sample and discover more about the report offerings @Urothelial Carcinoma Emerging Therapies
The urothelial carcinoma pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage urothelial carcinoma products, inactive and dormant assets, and a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the urothelial carcinoma pipeline landscape.
Urothelial Carcinoma Overview
Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer. In fact, if you have bladder cancer, it is almost certain to be a urothelial carcinoma. These cancers start in the urothelial cells that line the inside of the bladder. Urothelial cells also line other parts of the urinary tract, such as the part of the kidney that connects to the ureter (called the renal pelvis), the ureters, and the urethra. People with bladder cancer sometimes have tumors in these places, too, so all of the urinary tracts needs to be checked for tumors.
Understand more about the prevalent diabetic disease @Urothelial Carcinoma Pipeline Drugs Assessment
Urothelial Carcinoma Pipeline Drugs
Drug | Company | Phase | MoA | RoA |
OC-001 | Ocellaris Pharma, Inc. | Phase I/II | Undefined mechanism | Intravenous |
IK-175 | Ikena Oncology | Phase I | Aryl hydrocarbon receptor antagonist | Oral |
Rogaratinib | Bayer | Phase II/III | Type 1 fibroblast growth factor receptor antagonist | Oral |
MRx 518 | 4D Pharma PLC | Phase II | Toll-like receptor 5 agonist | Oral |
Vactosertib | MedPacto | Phase II | Transforming growth factor beta type I receptor antagonist | Oral |
Infigratinib | QED Therapeutics | Phase III | Type 1 fibroblast growth factor receptor antagonist | Oral |
RTX-224 | Rubius Therapeutics | Phase I/II | Natural killer cell stimulant | Intravenous |
TPST-1495 | Tempest Therapeutics | Phase I | Prostaglandin E EP2 receptor antagonist | Oral |
FLX475 | RAPT Therapeutics, Inc. | Phase I/II | CCR4 receptor antagonist | Oral |
Learn more about the novel and emerging @Urothelial Carcinoma Pipeline Analysis
Urothelial Carcinoma Therapeutics Assessment
The Urothelial Carcinoma Pipeline report proffers an integral view of the urothelial carcinoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Urothelial Carcinoma Pipeline Report
Coverage: Global
Therapeutic assessment by urothelial carcinoma product type: mono, combination, mono/combination
Therapeutic assessment by urothelial carcinoma clinical stages: Discovery, preclinical, Phase I, Phase II, Phase III, preregistration, inactive candidates
Therapeutics assessment by urothelial carcinoma route of administration: oral, parenteral, intravenous, subcutaneous, topical
Therapeutics assessment by urothelial carcinoma molecule type: monoclonal antibody, peptides, polymer, small molecule, gene therapy
Therapeutics assessment by urothelial carcinoma mechanism of action: Transforming growth factor-beta type I receptor antagonist, Aryl hydrocarbon receptor antagonist, Type 3 fibroblast growth factor receptor antagonist; Type 4 fibroblast growth factor receptor antagonist; Type-2 fibroblast growth factor receptor antagonist, Type 1 fibroblast growth factor receptor antagonist; Toll-like receptor 5 agonist, NF-kappa B modulator, Bacteria replacement; Prostaglandin E EP2 receptor antagonist; Natural killer cell stimulant; CCR4 receptor antagonist
Key urothelial carcinoma companies: Shandong TheraWisdom Biopharma Co., Ltd., Ikena Oncology, Ocellaris Pharma, Inc., Bayer, 4D Pharma PLC, MedPacto, QED Therapeutics, Bristol-Myers Squibb, Kyowa Kirin Pharmaceutical Development, Vyriad,Inc, Basilea Pharmaceutica, Pfizer, Daiichi Sankyo, Janssen Research & Development, LLC, Eli Lilly and Company, InnoCare Pharma, Kinnate Biopharma, Clovis Oncology, Gritstone Oncology, Xennials Therapeutics, Genome and Company , Exelixis, Atreca, Zentalis Pharmaceuticals, Celldex Therapeutics Inc , Nurix Therapeutics, Inc., Lipac Oncology LLC, TesoRx Pharma, LLC, Adaptimmune Therapeutics, Helsinn Group, Bicycle Therapeutica, Scholar Rock, Inc., Janux Therapeutics, Checkpoint Therapeutics, Inc., BioAtla, Inc., Cybrexa Therapeutics, Eisai Inc., Incyte Corporation, Shattuck Labs, Inc., Tempest Therapeutics, RAPT Therapeutics, Inc., Nektar Therapeutics, TAIHO PHARMACEUTICAL, Jazz Pharmaceuticals, Tyra Biosciences, Rubius Therapeutics, MacroGenics, BioNTech SE, Sorrento, and several others
Key urothelial carcinoma pipeline therapies: OC-001, IK-175, MRx 518, Rogaratinib, Vactosertib, Infigratinib, TWP-101, Ipilimumab, KHK 2455, MV-NIS, Derazantinib, Sasanlimab, Trastuzumab deruxtecan, TAR-200, Ramucirumab, ICP-192, KIN-3248, Rucaparib, GRANITE 001, NTX-301, GEN-001, XL092, ATRC-101, ZN-c3, CDX-527, NX-1607, TSD-001, CK-301, BA3071, CBX-12, E7130, INCB099280, SL-279252, TPST-1495, FLX475, NKTR-255, TAS0313, Lurbinectedin, TYRA-300, RTX-224, Enoblituzumab, GEN1046, Sti-3031, and many others
Dive deep into rich insights for emerging therapies and assessment, visit @Urothelial Carcinoma Pipeline Drugs
Table of Contents
1 | Introduction |
2 | Executive Summary |
3 | Urothelial Carcinoma: Overview |
4 | Pipeline Therapeutics |
5 | Late Stage Products (Phase III) |
5.1 | Infigratinib: QED Therapeutics |
6 | Mid Stage Products (Phase II) |
6.1 | MRx 518: 4D Pharma PLC |
7 | Early Stage Products (Phase I) |
7.1 | IK-175: Ikena Oncology |
8 | Therapeutic Assessment |
9 | Inactive Products |
10 | Collaborations Assessment – Licensing/Partnering/Funding |
11 | Urothelial Carcinoma – Unmet Needs |
12 | Urothelial Carcinoma – Market Drivers and Barriers |
13 | Appendix |
14 | About DelveInsight |
For further information on the urothelial carcinoma current pipeline therapeutics, reach out @Urothelial Carcinoma Ongoing Clinical Trials
Related Reports
Advanced Urothelial Carcinoma Pipeline
DelveInsight’s “Advanced Urothelial Carcinoma Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the advanced urothelial carcinoma pipeline landscape. It covers the pipeline drug profiles, clinical and non-clinical stage products, and key advanced urothelial carcinoma companies involved, such as Bayer, Mirati Therapeutics, etc.
DelveInsight’s Urinary Catheters Market Insights and Forecast report delivers an in-depth understanding of historical and forecasted urinary catheters market trends, market drivers, market barriers, and key companies involved, such as B. Braun Melsungen AG, Hangzhou Formed Medical Devices Co., Ltd., Boston Scientific Corporation, Cook, ConvaTec Inc., Becton, Dickinson, and Company., Teleflex Incorporated, etc.
Intrauterine Pressure Catheters Market
DelveInsight’s ‘Intrauterine Pressure Catheters – Market Insights, Competitive Landscape and Market Forecast – 2026’ report delivers an in-depth understanding of intrauterine pressure catheters and the historical and forecasted intrauterine pressure catheters market trends, market drivers, market barriers and key companies involved such as Koninklijke Philips NV, Utah Medical Products, Cardinal Health, CooperSurgical Inc, BD, Thomas Medical, Vyaire Medical, Terumo Europe NV, etc.
DelveInsight’s ‘Dialysis Catheters – Market Insights, Competitive Landscape, and Market Forecast – 2026’ report deliver an in-depth understanding of dialysis catheters and the historical and forecasted dialysis catheters market trends, market drivers, market barriers, and key companies involved such as Amecath Medical Technologies, Haidylena, Teleflex Incorporated, Nipro Corporation, Medtronic, Baxter, Wellex Medical, BD, etc.
DelveInsight’s ‘Urodynamic Devices Market Insights, Competitive Landscape, and Market Forecast – 2027’ report deliver an in-depth understanding of urodynamic devices and the historical and forecasted urodynamic devices market trends, market drivers, market barriers, and key companies involved, such as B Braun Meslungen AG, BestMedical, MINZE HEALTH, Santron Meditronic, Potent Medical, Laborie, MEDKONSULT medical technology s.r.o., The Prometheus Group®, HCItalia srl, DeltaMed, MEDICA S.P.A, etc.
Interested to know more about the breakthrough happenings? Take a look at the posts below
Data readout of potential ADCs: Enhertu gears up for Urothelial Carcinoma Market now
PARP inhibitors in Urothelial Carcinoma (UC): Hit or miss?
Rare Cancer Market: A Global Crusade on what is a ‘less common cancer?’
Top 5 Cancers Creating Major Challenge To The Global Healthcare System
Other Trending Healthcare Reports
About DelveInsight
DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
